nach oben

Journal of Nephrology

Erschienen in:

01.08.2019 | Original Article

Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use prior to medical intensive care unit admission and in-hospital mortality: propensity score-matched cohort study

verfasst von: Daiki Kobayashi, Nagato Kuriyama, Fumitaka Yanase, Osamu Takahashi, Kazuhiro Aoki, Yasuhiro Komatsu

Erschienen in: Journal of Nephrology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

The aim of this study was to evaluate whether angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker (ACEI/ARB) use prior to medical intensive care unit (ICU) admission was associated with in-hospital mortality and length of ICU stay.

Methods

A propensity score-matched cohort study was conducted at single center from 2004 to 2016. We included all adult patients who were admitted to the ICU due to internal medicine-related conditions. We compared patients who had used ACEIs/ARBs prior to ICU admission to patients who had not. Our primary and secondary outcomes were in-hospital mortality and length of stay among survivors and the deceased. Propensity scores were calculated via logistic regression analyses with forward stepwise selection. An odds ratio (OR) for primary outcome was calculated via logistic regression. Sensitivity analyses were performed using conditional logistic regression models including different sets of covariates to confirm our results.

Results

3095 patients were admitted to the ICU. Overall, 693 patients were identified via matching, 231 of whom had used ACEIs/ARBs and 462 of whom had not. None of the baseline characteristics differed significantly between groups. Among them, 131 (18.9%) died. Those who had used ACEIs/ARBs had a lower rate of mortality (p < 0.01). Length of ICU stay did not differ significantly between those with ACEIs/ARBs and those without among survivors (p = 0.43) and the deceased (p = 0.14). The OR for mortality was 0.51 (95% confidence interval 0.32–0.79). The results of the sensitivity analyses confirmed the results (ORs 0.4 6–0.53; all were statistically significant).

Conclusion

Prior ACEI/ARB use may be related to in-hospital mortality among medical ICU patients.

Sjoding MW, Prescott HC, Wunsch H, Iwashyna TJ, Cooke CR (2016) Longitudinal changes in ICU admissions among elderly patients in the United States. Crit Care Med 44(7):1353–1360CrossRef

Adhikari NK, Fowler RA, Bhagwanjee S, Rubenfeld GD (2010) Critical care and the global burden of critical illness in adults. Lancet 376(9749):1339–1346CrossRef

Suka M, Yoshida K, Takezawa J (2004) Impact of intensive care unit-acquired infection on hospital mortality in Japan: a multicenter cohort study. Environ Health Prev Med 9(2):53–57CrossRef

Woolfson RG, Poston L (1991) Effect of ouabain on endothelium-dependent relaxation of human resistance arteries. Hypertension 17(5):619–625CrossRef

Annane D, Aegerter P, Jars-Guincestre MC, Guidet B (2003) Network CU-R. Current epidemiology of septic shock: the CUB-Rea network. Am J Respir Crit Care Med 168(2):165–172CrossRef

Sanfilippo F, Santonocito C, Morelli A, Foex P (2015) Beta-blocker use in severe sepsis and septic shock: a systematic review. Curr Med Res Opin 31(10):1817–1825CrossRef

Fuchs C, Wauschkuhn S, Scheer C et al (2017) Continuing chronic beta-blockade in the acute phase of severe sepsis and septic shock is associated with decreased mortality rates up to 90 days. Br J Anaesth 119(4):616–625CrossRef

Magder SA (2012) The ups and downs of heart rate. Crit Care Med 40(1):239–245CrossRef

Schmittinger CA, Torgersen C, Luckner G, Schroder DC, Lorenz I, Dunser MW (2012) Adverse cardiac events during catecholamine vasopressor therapy: a prospective observational study. Intensive Care Med 38(6):950–958CrossRef

10.

Sander O, Welters ID, Foex P, Sear JW (2005) Impact of prolonged elevated heart rate on incidence of major cardiac events in critically ill patients with a high risk of cardiac complications. Crit Care Med 33(1):81–88 (discussion 241–242) CrossRef

11.

Mochizuki M, Yano M, Oda T et al (2007) Scavenging free radicals by low-dose carvedilol prevents redox-dependent Ca2+ leak via stabilization of ryanodine receptor in heart failure. J Am Coll Cardiol 49(16):1722–1732CrossRef

12.

Rudiger A, Singer M (2007) Mechanisms of sepsis-induced cardiac dysfunction. Crit Care Med 35(6):1599–1608CrossRef

13.

Cohen RI (2010) Sepsis-induced myocardial dysfunction: linking physiology and genomics. Crit Care Med 38(3):1001–1002CrossRef

14.

Park JH, Kang SJ, Song JK et al (2005) Left ventricular apical ballooning due to severe physical stress in patients admitted to the medical ICU. Chest 128(1):296–302CrossRef

15.

Shen JI, Saxena AB, Montez-Rath ME, Leng L, Chang TI, Winkelmayer WC (2017) Comparative effectiveness of angiotensin receptor blockers vs. angiotensin-converting enzyme inhibitors on cardiovascular outcomes in patients initiating peritoneal dialysis. J Nephrol 30(2):281–288CrossRef

16.

Schmidt M, Mansfield KE, Bhaskaran K et al (2017) Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study. BMJ 356:j791CrossRef

17.

Heidenreich PA, Zhao X, Hernandez AF, Yancy CW, Fonarow GC (2012) Patient and hospital characteristics associated with traditional measures of inpatient quality of care for patients with heart failure. Am Heart J. 163(2):239–245.e233CrossRef

18.

Elder DH, Wei L, Szwejkowski BR et al (2011) The impact of renin-angiotensin-aldosterone system blockade on heart failure outcomes and mortality in patients identified to have aortic regurgitation: a large population cohort study. J Am Coll Cardiol 58(20):2084–2091CrossRef

19.

Kasama S, Toyama T, Kumakura H et al (2005) Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. J Am Coll Cardiol 45(5):661–667CrossRef

20.

Evans M, Carrero JJ, Szummer K et al (2016) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in myocardial infarction patients with renal dysfunction. J Am Coll Cardiol 67(14):1687–1697CrossRef

21.

White CM, Kluger J, Lertsburapa K, Faheem O, Coleman CI (2007) Effect of preoperative angiotensin converting enzyme inhibitor or angiotensin receptor blocker use on the frequency of atrial fibrillation after cardiac surgery: a cohort study from the atrial fibrillation suppression trials II and III. Eur J Cardiothorac Surg 31(5):817–820CrossRef

22.

Mortensen EM, Restrepo MI, Anzueto A, Pugh J (2005) The impact of prior outpatient ACE inhibitor use on 30-day mortality for patients hospitalized with community-acquired pneumonia. BMC Pulm Med 5:12CrossRef

23.

Mortensen EM, Copeland LA, Pugh MJ et al (2009) Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 10:45CrossRef

24.

Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383CrossRef

25.

Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985) APACHE II: a severity of disease classification system. Crit Care Med 13(10):818–829CrossRef

26.

Vincent JL, Moreno R, Takala J et al (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22(7):707–710CrossRef

27.

Sykes L, Nipah R, Kalra P, Green D (2018) A narrative review of the impact of interventions in acute kidney injury. J Nephrol 31(4):523–535CrossRef

28.

Kellum JA, Lameire N, Aspelin P et al (2012) Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2(1):1–138CrossRef

29.

Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T (2006) Variable selection for propensity score models. Am J Epidemiol 163(12):1149–1156CrossRef

30.

Austin PC (2010) Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score. Am J Epidemiol 172(9):1092–1097CrossRef

31.

Kelly JG, O’Malley K (1990) Clinical pharmacokinetics of the newer ACE inhibitors. A review. Clin Pharmacokinet 19(3):177–196CrossRef

32.

British Hypertension Society (2008) Angiotensin Receptor Blockers (ARBs). http://www.bhsoc.org/pdfs/therapeutics/Angiotensin%20Receptor%20Blockers%20(ARBs).pdf. Accessed 25 March 2017

33.

Ahmed AK, Kamath NS, El Kossi M, El Nahas AM (2010) The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant 25(12):3977–3982CrossRef

34.

Doerschug KC, Delsing AS, Schmidt GA, Ashare A (2010) Renin-angiotensin system activation correlates with microvascular dysfunction in a prospective cohort study of clinical sepsis. Crit Care 14(1):R24CrossRef

35.

Correa TD, Takala J, Jakob SM (2015) Angiotensin II in septic shock. Crit Care 19:98CrossRef

36.

Fani F, Regolisti G, Delsante M et al (2018) Recent advances in the pathogenetic mechanisms of sepsis-associated acute kidney injury. J Nephrol 31(3):351–359CrossRef

37.

Cave AC, Brewer AC, Narayanapanicker A et al (2006) NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal 8(5–6):691–728CrossRef

38.

Negi SI, Jeong EM, Shukrullah I et al (2015) Renin-angiotensin activation and oxidative stress in early heart failure with preserved ejection fraction. Biomed Res Int 2015:825027CrossRef

39.

The SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325(5):293–302CrossRef

40.

Santos-Gallego CG, Vahl TP, Goliasch G et al (2016) Sphingosine-1-phosphate receptor agonist fingolimod increases myocardial salvage and decreases adverse postinfarction left ventricular remodeling in a porcine model of ischemia/reperfusion. Circulation 133(10):954–966CrossRef

41.

Stiefel P, Vallejo-Vaz AJ, Garcia Morillo S, Villar J (2011) Role of the Renin-Angiotensin system and aldosterone on cardiometabolic syndrome. Int J Hypertens 2011:685238CrossRef

42.

Kuriyama N, Mizuno T, Niwa F, Watanabe Y, Nakagawa M (2010) Autonomic nervous dysfunction during acute cerebral infarction. Neurol Res 32(8):821–827CrossRef

43.

Johansson P, Stensballe J, Ostrowski S (2017) Shock induced endotheliopathy (SHINE) in acute critical illness—a unifying pathophysiologic mechanism. Crit Care 21(1):25CrossRef

44.

Chawla LS, Busse L, Brasha-Mitchell E et al (2014) Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. Crit Care 18(5):534CrossRef

45.

Vallejos A, Olivares P, Varela D et al (2018) Preventive leptin administration protects against sepsis through improving hypotension, tachycardia, oxidative stress burst, multiple organ dysfunction, and increasing survival. Front Physiol 9:1800CrossRef

46.

Yamada T, Shojima N, Noma H, Yamauchi T, Kadowaki T (2017) Glycemic control, mortality, and hypoglycemia in critically ill patients: a systematic review and network meta-analysis of randomized controlled trials. Intensive Care Med 43(1):1–15CrossRef

47.

Orban JC, Walrave Y, Mongardon N et al (2017) Causes and characteristics of death in intensive care units: a prospective multicenter study. Anesthesiology 126(5):882–889CrossRef

48.

Hill AB (1965) The environment and disease: association or causation? Proc R Soc Med 58:295–300PubMedPubMedCentral

49.

Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Martinez Ubago JL (2002) Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105(21):2512–2517CrossRef

50.

Mottram PM, Haluska B, Leano R, Cowley D, Stowasser M, Marwick TH (2004) Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 110(5):558–565CrossRef

Titel: Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use prior to medical intensive care unit admission and in-hospital mortality: propensity score-matched cohort study
verfasst von: Daiki Kobayashi
Nagato Kuriyama
Fumitaka Yanase
Osamu Takahashi
Kazuhiro Aoki
Yasuhiro Komatsu
Publikationsdatum: 01.08.2019
Verlag: Springer International Publishing
Erschienen in: Journal of Nephrology / Ausgabe 4/2019
Print ISSN: 1121-8428
Elektronische ISSN: 1724-6059
DOI: https://doi.org/10.1007/s40620-019-00603-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use prior to medical intensive care unit admission and in-hospital mortality: propensity score-matched cohort study